Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
44 hedge funds and large institutions have $18.7M invested in Regulus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 12 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
10% more call options, than puts
Call options by funds: $376K | Put options by funds: $343K
0% more funds holding
Funds holding: 44 → 44 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
0.68% less ownership
Funds ownership: 3.76% → 3.08% (-0.68%)
56% less capital invested
Capital invested by funds: $42.6M → $18.7M (-$23.8M)
Top Buyers
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.02M |
| 2 |
Two Sigma Investments
New York
|
-$1.67M |
| 3 |
Two Sigma Advisers
New York
|
-$1.31M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$597K |
| 5 |
AI
Atom Investors
Austin,
Texas
|
-$526K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Goldman Sachs
New York
| – | -$28K | -1,805 | Closed |
|
|
PAG
52
Private Advisor Group
Morristown,
New Jersey
| – | -$16K | -1,000 | Closed |
|
|
VFA
53
Valeo Financial Advisors
Carmel,
Indiana
| – | -$7K | -423 | Closed |
|
|
CA
54
Clearstead Advisors
Cleveland,
Ohio
| – | -$2K | -100 | Closed |
|
|
FDCDDQ
55
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$129 | -8 | Closed |
|
RGLS Hedge Fund Activity: Q2 2021 in Review
44 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2021, worth a combined $18.7M — down 56% from $42.6M a quarter earlier.
Fund positioning in RGLS was balanced in Q2 2021: 12 funds opened new positions, 12 closed out, 14 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $375K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $5.02M sold.
- 44 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $18.7M of Regulus Therapeutics stock for Q2 2021, down 56% quarter-over-quarter.
- 12 funds opened new Regulus Therapeutics positions in Q2 2021 and 12 closed out, a net change of 0 holders.
- The largest Regulus Therapeutics buyer in Q2 2021 was Morgan Stanley, an estimated $375K added.
- The largest Regulus Therapeutics seller in Q2 2021 was Point72 Asset Management, an estimated $5.02M sold.
Based on aggregated 13F filings for Q2 2021.